Healthcare / Diagnostics & ResearchNasdaqCM
$10.44
-0.26 (-2.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-30.7M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.9%
↓Gross Margin
43.2%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3.0%
FCF / Net income
0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $727.3M · net income $-108.0M · FCF $-21.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $727.3M | $727.3M | $660.6M | $591.6M | $509.7M | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-108.0M | $-108.0M | $-78.7M | $-88.0M | $-144.3M | $-8.3M | $4.2M | $8.0M | $2.6M | $-396000.00 | $-6.1M | $-2.5M | $1.1M | $2.0M | $65000.00 | $-1.2M | $-3.3M |
| EBITDA | $-38.7M | $-38.7M | $-1.5M | $-17.6M | $-82.3M | — | $11.9M | $33.4M | $25.8M | $18.5M | $18.1M | $1.1M | $7.6M | $7.4M | $4.8M | — | — |
| EPS | -0.84 | -0.84 | -0.62 | -0.70 | -1.16 | — | — | — | — | — | — | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | — |
| Gross Margin | 43.2% | 43.2% | 43.9% | 41.3% | 36.9% | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -12.1% | -12.1% | -12.9% | -16.3% | -30.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -14.9% | -14.9% | -11.9% | -14.9% | -28.3% | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.49 | 0.49 | 0.67 | 0.65 | 0.61 | — | — | — | 0.29 | 0.53 | 0.57 | 0.25 | — | — | — | — | — |
| Current Ratio | 4.42 | 4.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-21.8M | $-21.8M | $-34.0M | $-30.7M | $-96.9M | $-90.9M | $-27.6M | $3.3M | $30.5M | $4.3M | — | — | — | $216000.00 | $-3.1M | $-828000.00 | $-3.0M |
| Returns | |||||||||||||||||
| ROE | -12.9% | -12.9% | -8.7% | -9.3% | -14.5% | -0.8% | 0.6% | 1.6% | 0.8% | -0.2% | -3.8% | -1.2% | 1.9% | 9.4% | 0.7% | -20.0% | -105.4% |
| Valuation | |||||||||||||||||
| P/B | 1.56 | 1.56 | 2.38 | 2.08 | 1.15 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 10.1% | 10.1% | 11.6% | 16.1% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | -35.5% | -35.5% | 11.4% | 39.7% | — | — | — | — | — | — | — | -300.0% | -50.0% | — | 100.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.62 → -0.84
Residual
+42.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.